Mitral stenosis still a concern in heart valve diseases  by Iung, Bernard
Archives of Cardiovascular Disease (2008) 101, 597—599
Disponib le en l igne sur www.sc iencedi rec t .com
SCIENTIFIC EDITORIAL
Mitral stenosis still a concern in heart valve diseases
Le rétrécissement mitral : une valvulopathie encore d’actualité
Bernard Iung ∗
Cardiology department, Bichat hospital, AP—HP, 46, rue Henri-Huchard, 75018 Paris, France
Received 11 September 2008; accepted 12 September 2008
Available online 8 November 2008KEYWORDS
Mitral stenosis;
Rheumatic fever;
Epidemiology;
Balloon mitral
commissurotomy;
Heart valve disease
MOTS CLÉS
Rétrécissement
mitral ;
Rhumatisme
articulaire ;
Épidémiologie ;
Dilatation mitrale
percutanée ;
Valvulopathie
 This editorial refers to: What ar
the world and do they inﬂuence the
∗ Fax: +33 1 40 25 67 32.
1875-2136/$ — see front matter ©
doi:10.1016/j.acvd.2008.09.003In Western countries, valvular heart diseases are mainly the result of so-called degen-
erative aetiologies, which has consequences for patient characteristics and the way in
which the different types of heart valve disease are distributed [1,2]. Aortic stenosis
and mitral regurgitation are now the most frequently occurring heart valve diseases in
Western countries; their prevalence is low below the age of 65-years and increases sharply
thereafter. Conversely, there has been a decrease in the prevalence of mitral stenosis,
which is the only heart valve disease that is still caused predominantly by rheumatic
fever. Nevertheless, mitral stenosis has not disappeared in Western countries, where it
still accounts for more than 10% of single native valve diseases [1]. In addition, it remains
a major public health issue in developing countries.
In this issue of the Archives of cardiovascular diseases, a paper by Marijon et al.
highlights the diversity in the characteristics of patients presenting with mitral stenosis
worldwide [3]. Although there have been a number of series on percutaneous mitral
commissurotomy originating from Western and developing countries, this is the ﬁrst study
designed speciﬁcally to compare patient characteristics and the results of percutaneous
mitral commissurotomy in seven countries from the ﬁve continents. All participating
centres were high-volume centres, which limits the bias inherent in such an observational
study. In comparison with patients from Western countries, patients from developing
countries were markedly younger, had more severe valve stenosis and less frequent atrial
ﬁbrillation. Despite differences in patient presentation, there were no differences in the
immediate results of percutaneous mitral commissurotomy.These ﬁndings highlight major differences in the spectrum of rheumatic heart disease
across developing and Western countries. Probably the most important difference is
related to prevalence. Series from India and Pakistan have reported a prevalence of
chronic rheumatic heart disease of around 5 per 1000 in schoolchildren [4,5]. According to
e the differences in presentation of candidates for percutaneous mitral commissurotomy across
results of the procedure? Marijon E, Iung B, Mocumbi AO.
2008 Elsevier Masson SAS. All rights reserved.
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he World Health Organisation, prevalence rates are esti-
ated at between 2 and 15 per 1000 in schoolchildren
nd adolescents in Africa [6]. These ﬁgures are likely to
e underestimated as they are generally obtained using
linical screening, with or without conﬁrmation by echocar-
iographic examination. It has recently been shown that
ystematic echocardiographic screening leads to higher
revalence rates. In a series of 5847 children from Cambodia
nd Mozambique, the respective prevalences of rheumatic
eart valve disease were estimated at 21.5 and 30.4
er 1000 using systematic echocardiographic screening,
hereas the corresponding estimations were 2.2 and 2.3 per
000, respectively, using clinical screening alone [7]. Con-
ersely, the prevalence of rheumatic heart valve disease is
stimated to be less than 0.5 per 1000 in Western countries.
Unequal burden of streptococcal infections is the main
ause of differences in the prevalence of rheumatic heart
isease between countries. Poor socioeconomic environ-
ent is an important factor in promoting the spread of
treptococcal infections, which is further exacerbated by
n inadequate health system, leading to missed diagnosis
nd a lack of implementation of secondary prevention
easures. Streptococcal infection burden is also a strong
eterminant for the progression from acute carditis to
evere chronic rheumatic heart valve disease. In a prospec-
ive study from Brazil, a multivariable analysis identiﬁed
hree predictive factors of progression towards severe
hronic rheumatic heart valve disease: the severity of
nitial carditis; recurrences of acute rheumatic fever; and
ow maternal educational level [8].
The more rapid progression of valve lesions in countries
here streptococcal infection burden is high accounts
or the younger age and smaller valve areas observed
n patients with severe symptomatic mitral stenosis in
he paper by Marijon et al. [3]. The older age and less
evere degree of mitral stenosis in patients presenting with
heumatic heart disease in Western countries can be related
o two main factors, which are linked to the decrease in
he incidence of acute rheumatic fever:
patients were children or adolescents when rheumatic
fever was still endemic in Europe and the United States;
they experienced a subsequent slower progression of their
valve disease.
There is growing evidence, however, that the relationship
etween streptococcal infection and rheumatic heart dis-
ase is not straightforward. There is an important variability
n individual susceptibility to rheumatic fever, which raises
he question of the possible involvement of other envi-
onmental or genetic factors [6,9]. None of these possible
ofactors has been clearly identiﬁed. The female predomi-
ance in all seven centres in the study by Marijon et al. is an
llustration of the heterogeneous susceptibility to rheumatic
ever, which is consistent with other series but remains
nexplained. The involvement of factors other than Strep-
ococcus in the development of rheumatic heart disease has
mportant implications for prevention strategies and may
rovide an explanation for the failure of prevention of acute
heumatic fever based on antibiotic prescription alone.
Given the persisting high prevalence of rheumatic fever
nd the shortcomings of prevention strategies in developing
ountries, it is therefore expected that chronic rheumatic
o
n
b
p
dB. Iung
eart valve diseases —particularly mitral stenosis— will
emain prevalent in the near future. This is particularly
rue for developing countries but will also concern Western
ountries as a result of immigration.
Besides patient presentation, the other main ﬁnding
f the paper by Marijon et al. conﬁrms the efﬁcacy of
ercutaneous mitral commissurotomy in a wide range of
atients. The consistently low rate of complications in these
even high-volume centres is further proof of the safety of
ercutaneous mitral commissurotomy in experienced hands.
he availability of a conservative procedure is of particular
mportance in developing countries because of the draw-
acks of heart valve prosthesis. Structural deterioration of
ioprosthesis occurs rapidly in young patients —even more
o in the mitral than in the aortic position— and lifelong
nticoagulant therapy is difﬁcult to manage in this context.
andomized series have shown that the long-term results of
ercutaneous mitral commissurotomy are at least as good as
hose of surgical commissurotomy [10]. However, surgical or
ercutaneous mitral commissurotomy remains a palliative
rocedure because valve remodeling is a persisting process
ver time in chronic rheumatic heart valve diseases.
hus, the possibility of repeating percutaneous mitral
ommissurotomy is attractive in young patients, in whom
t avoids repeated surgical interventions. Although it is a
articularly appropriate procedure in developing countries,
ercutaneous mitral commissurotomy is underused because
f economic constraints, which explains why closed-heart
ommissurotomy remains a widely-used treatment in these
ountries [11].
Most patients from Western countries have less favorable
resenting characteristics for percutaneous mitral commis-
urotomy than younger patients from developing countries.
evertheless, they may derive a beneﬁt from percutaneous
itral commissurotomy, provided that patient selection
akes into account all their characteristics, including, but
ot overemphasizing, echocardiographic analysis of valve
natomy [12]. The safety of percutaneous mitral commis-
urotomy is also an incentive to consider intervention at
n early stage of the disease in patients who present with
avorable characteristics [12]. In addition, the low risk
nherent in percutaneous mitral commissurotomy makes it
useful procedure in patients who are at particularly high
isk for surgery.
At the present time, when most attention on heart valve
iseases is focused on aortic stenosis and mitral regurgita-
ion, one must not forget that rheumatic heart diseases, in
articular mitral stenosis, remain highly prevalent world-
ide and are still encountered in Western countries. This
ustiﬁes a continuing awareness to allow for timely inter-
ention, particularly given the availability of percutaneous
itral commissurotomy, which enables effective treatment
o be performed at low risk in a wide range of patients. Per-
utaneous mitral commissurotomy is now a well-established
echnique, which has not replaced surgery but complements
t at different stages of the disease. This has been made
ossible as a result of continuing prospective evaluations
f the technique performed by experienced centres. The
eed for thorough evaluations of new techniques should
e underlined given the current development of new
ercutaneous approaches in the treatment of heart valve
iseases.
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